Baxter seeks European marketing authorization for HyQ to treat PI

Baxter International Inc. announced today that it has submitted an application to the European Medicines Agency's Committee for Human Medicinal Products seeking marketing authorization for HyQ. HyQ is Baxter's investigational immunoglobulin (IG) therapy administered subcutaneously and facilitated by recombinant human hyaluronidase, a dispersion and permeation enhancer, for use in patients with primary immunodeficiencies (PI).

"We understand the challenges faced by patients with PI and know they are in need of new options that can reduce the burden of treating the disease," said Professor Hartmut Ehrlich, vice president, research and development, Baxter's BioScience business. "The trial we conducted found that the combination of our IG with this dispersion enhancing enzyme will facilitate subcutaneous administration and, if approved, may become an important new therapeutic option for this patient community."

The submission, which follows a similar application submitted to the United States Food and Drug Administration (FDA) earlier this year, is based on results from a phase III, prospective, open-label, non-controlled design clinical trial, which evaluated the safety and effectiveness of HyQ in the prevention of acute serious bacterial infections, and the pharmacokinetic parameters of HyQ compared to IG administered intravenously.

The objective of the study was to infuse HyQ at a 3 or 4 week IG dose in a single site. The acute serious bacterial infection rate in the study was 0.025 per patient per year, which is below the required efficacy threshold of 1.0. In the tolerability assessment of HyQ, the most frequently reported adverse reactions were infusion site reactions (20% of infusions), headache (3% of infusions), fatigue (1% of infusions) and pyrexia (fever) (1% of infusions). Baxter will be presenting study results during the American College of Allergy, Asthma and Immunology (ACAAI) annual meeting in Boston in November.

"Along with our development progress in markets around the world, the submission of our European MAA for HyQ is another important milestone in our efforts to deliver valuable new options that will benefit physicians and their patients," said Ludwig Hantson, president, Baxter's BioScience business. "These efforts reinforce our ongoing commitment to innovation in delivering new therapy options for patients with these difficult to manage conditions."

Source:

Baxter

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Baxter International Inc.. (2019, June 19). Baxter seeks European marketing authorization for HyQ to treat PI. News-Medical. Retrieved on February 04, 2023 from https://www.news-medical.net/news/20111001/Baxter-seeks-European-marketing-authorization-for-HyQ-to-treat-PI.aspx.

  • MLA

    Baxter International Inc.. "Baxter seeks European marketing authorization for HyQ to treat PI". News-Medical. 04 February 2023. <https://www.news-medical.net/news/20111001/Baxter-seeks-European-marketing-authorization-for-HyQ-to-treat-PI.aspx>.

  • Chicago

    Baxter International Inc.. "Baxter seeks European marketing authorization for HyQ to treat PI". News-Medical. https://www.news-medical.net/news/20111001/Baxter-seeks-European-marketing-authorization-for-HyQ-to-treat-PI.aspx. (accessed February 04, 2023).

  • Harvard

    Baxter International Inc.. 2019. Baxter seeks European marketing authorization for HyQ to treat PI. News-Medical, viewed 04 February 2023, https://www.news-medical.net/news/20111001/Baxter-seeks-European-marketing-authorization-for-HyQ-to-treat-PI.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
Baxter reports topline results from BAX 111 Phase 3 trial for treatment of von Willebrand disease